Clinical trial results show that the anthelmintic ivermectin has the effect of lowering the corona 19 mortality rate by up to 80%.
The same results were found in 11 clinical trials involving a total of 1,400 COVID-19 patients in developing countries such as Egypt, Argentina, and Bangladesh, the UK's Daily Mail Internet Edition reported on the 4th.
According to a comprehensive analysis of the entire clinical trial data by Dr. Andrew Hill, a virus expert at the University of Liverpool in the UK, 8 out of 573 patients receiving ivermectin and 44 out of 510 patients receiving placebo died. Appeared, the newspaper said.
Ivermectin has also been shown to significantly shorten the time it takes for the corona19 virus to be removed from the patient's body, Dr. Hill said.
In a clinical trial of 200 patients with mild symptoms in Egypt, 100 people who received ivermectin cleared the corona 19 virus within 5 days, while 100 people who received placebo took 10 days for the virus to disappear.
In a clinical trial in 200 severely ill patients, the time it took for the virus to disappear was 6 days for 100 patients receiving ivermectin and 12 days for 100 patients receiving placebo.
Similar results were obtained in a clinical trial conducted in Bangladesh.
Most of the doses of ivermectin used in clinical trials were 0.2-0.6mg/kg, but there was also one clinical trial in which a high dose of 12mg was administered.
These clinical trials were commissioned by the World Health Organization (WHO) and were conducted primarily in developing countries.
In early April, a research team at Monash University in Australia announced the results of an in vitro test that the genetic material of the corona 19 virus exposed to ivermectin disappeared within 48 hours, and then clinical trials have been conducted on corona 19 patients in various places around the world. There is.
These 11 clinical trials were conducted in part by double blind, which is the optimal standard method for clinical trials, and part by open label.
Double-blindness prevents both participants and clinicians from knowing to whom the test drug and placebo will be administered, and the method of disclosure is to let all participants know.
The results of other ivermectin clinical trials involving a total of 7,100 COVID-19 patients are expected to be released in the coming months.
However, some of the medical community have expressed doubts about the results, saying that most clinical trials have a small number of participants, poor design, different ivermectin doses used, and in some cases co-administered with other drugs.
Many experts fear that ivermectin will follow the route of hydroxychloroquine, a malaria treatment that proved ineffective after U.S. President Trump promised to be a ``game changer'' for COVID-19 treatment.
Ivermectin is an insect repellent developed in the 1970s and is an inexpensive drug widely used to treat parasitic infections such as head lice and scabies.
Scientists researching ivermectin as a treatment for COVID-19 believe that the drug interferes with the life cycle of the COVID-19 virus.
Side effects of ivermectin were leg swelling, constipation, and eye irritation.
It is known that ivermectin can cause a sudden drop in blood pressure, liver damage, vomiting, diarrhea, abdominal pain, and dizziness when used in combination with other medications.
(Photo = Courtesy of Getty Image Bank, Yonhap News)